CD86 and rheumatoid arthritis: analyzed the peripheral blood of 20 therapy-naive RA patients using a 23-marker mass cytometry (CyTOF) antibody panel and reported the following markers: p-p38, IkBa, p-cJun, p-NFkB, and CD86 in the cells of both the myeloid innate and adaptive branches (memory CD4+ T cells) of the immune system as potential markers for discriminating patients with RA from healthy donors (22).